研报掘金丨中金：下调康方生物目标价至184港元 维持“跑赢行业”评级

Core Insights - The report from CICC highlights that Kangfang Biotech recently presented impressive interim analysis data from the HARMONi-6 trial at The Lancet & ESMO [1] - The company has revised the HARMONi-3 trial protocol to conduct independent statistical analysis based on histological types for the primary endpoint [1] - CICC believes that separate analysis will help the company obtain clinical data earlier and that increasing the enrolled population will contribute to better overall survival (OS) performance [1] Financial Projections - CICC maintains the profit forecasts for Kangfang Biotech at 0.09 CNY for 2025 and 0.59 CNY for 2026 [1] - The firm continues to rate the company as "outperforming the industry" [1] - Due to a downward adjustment in the valuation midpoint for innovative drugs in the Hong Kong stock market, CICC has reduced the target price by 18.2% to 184 HKD [1]